Sinopharm Tech Holdings Limited expects to record a profit attributable to equity holders of the Company of not less than HKD 15.0 million for the six months ended 31 December 2022, as compared with a loss attributable to equity holders of the Company of approximately HKD 13.5 million for the corresponding period in 2021.